[A case of etanercept-induced pneumonitis].
A 64-year-old man was admitted to our hospital because of fever and dyspnea with marked hypoxemia and diffuse ground-glass opacities in bilateral lung fields revealed by a chest CT scan. He had used etanercept therapy for his rheumatoid arthritis. His PaO2/FiO2 had decreased to 130.4 Torr. On bronchoalveolar lavage, lymphocytes were elevated to 54.4% and bacteria culture was negative. We diagnosed drug-induced pneumonitis caused by etanercept, clinically and started high dose corticosteroid therapy. Despite his severe hypoxemia, the corticosteroid therapy and use of non-invasive positive pressure ventilation improved his condition. Interstitial lung disease induced by etanercept is rare, and a severe case requiring mechanical ventilation has never been reported. Because of the critical condition it can cause, it is suggested that evaluation of interstitial pneumonia is crucial.
Yokoyama
Toshiki
T
First Department of Internal Medicine, Shinshu University School of Medicine.
Yamamoto
Hiroshi
H
Fukushima
Toshiro
T
Agatsuma
Toshihiko
T
Ushiki
Atsuhito
A
Matsubara
Mikako
M
Kobayashi
Takashi
T
Tanabe
Tsuyoshi
T
Yasuo
Masanori
M
Urusihata
Kazuhisa
K
Hanaoka
Masayuki
M
Koizumi
Tomonobu
T
Fujimoto
Keisaku
K
Kubo
Keishi
K
D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011014:Pneumonia / Q000139:chemically induced*; D018124:Receptors, Tumor Necrosis Factor
D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept